Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
23 September 2020 | Story Leonie Bolleurs | Photo Supplied
Participants in the third Amazing Race travelled through the African continent, experiencing Africa’s roots and its rich, vibrant, and diverse cultures

During the third Amazing Race presented by Organisational Development and Employee Wellness, staff had the opportunity to virtually travel through Africa. 

The aim of the race with the theme, A Journey through Africa, was to celebrate South Africa and Africa’s roots and its rich, vibrant, and diverse cultures. 

Natasha Nel, organisational development specialist and organiser of the race, says they wanted to give the 13 participating teams the opportunity to explore, learn, create, and be challenged together as they travel to some of the most interesting and exotic locations around Africa, but also in South Africa. 

Here in our own country, teams had the opportunity to experience our culture as well as the diversity of beliefs and traditions.


Here in our own country, teams had the opportunity to experience our culture as well as the diversity of beliefs and traditions.

Interactive and exciting event

Nel says staff could join the race in the convenience of their personal working space via a Zoom meeting. “They only needed to download the game that was specifically tailored for the UFS.” 

“It was a fun, interactive, and exciting event. In this unique adventure, it was interesting to see how teams worked together, made decisions, and also thought outside the box during the challenges,” she says.

Nel explains that teams were requested to take photos, answer questions, and make decisions unique to Africa and their culture. Some decisions and answers were timed. They also had to decide where they wanted to travel, but each decision and option had its costs, reward, and challenge linked to it.

We are the champions

Chanel Lewis, Aneke Kruger, Runé van der Merwe, and Lischen du Randt walked away as winners of the third Amazing Race. 

By participating in this race, the university has sponsored 13 breakfasts for the Community Chest of South Africa (this organisation’s mission is to inspire and facilitate community giving for community enhancement).


News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept